Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. STXS
stocks logo

STXS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
9.15M
+44.32%
-0.063
-30.56%
9.20M
+23.13%
-0.055
-21.43%
10.17M
+15.56%
-0.053
+6.66%
Estimates Revision
The market is revising Downward the revenue expectations for Stereotaxis, Inc. (STXS) for FY2025, with the revenue forecasts being adjusted by -4.97% over the past three months. During the same period, the stock price has changed by -16.21%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.97%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+10.87%
In Past 3 Month
Stock Price
Go Down
down Image
-16.21%
In Past 3 Month
Wall Street analysts forecast STXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STXS is 4.33 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast STXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STXS is 4.33 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.430
sliders
Low
4.00
Averages
4.33
High
5.00
Current: 2.430
sliders
Low
4.00
Averages
4.33
High
5.00
Roth Capital
NULL
to
Buy
initiated
$4
2025-11-05
Reason
Roth Capital
Price Target
$4
2025-11-05
initiated
NULL
to
Buy
Reason
Roth Capital resumed coverage of Stereotaxis with a Buy rating and $4 price target. The firm believes the company is positioned for long-term revenue growth and profitability from continued adoption of its Robotic Magnetic Navigation technology along with "imminent" regulatory approvals and subsequent commercial launches of its product pipeline.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Stereotaxis Inc (STXS.A) is -11.26, compared to its 5-year average forward P/E of -17.74. For a more detailed relative valuation and DCF analysis to assess Stereotaxis Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-17.74
Current PE
-11.26
Overvalued PE
-2.63
Undervalued PE
-32.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-33.37
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-4.62
Undervalued EV/EBITDA
-62.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.95
Current PS
0.00
Overvalued PS
10.55
Undervalued PS
3.35
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

STXS News & Events

Events Timeline

(ET)
2025-11-11
16:03:35
Stereotaxis Announces Q3 Earnings Per Share of 7 Cents, Exceeding Consensus Estimate of 6 Cents
select
2025-11-10 (ET)
2025-11-10
16:55:38
Stereotaxis Receives FDA Approval for GenesisX
select
2025-10-15 (ET)
2025-10-15
07:34:05
Stereotaxis Reveals EU Launch and Submits 510k for Synchrony System
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-26NASDAQ.COM
Will Refurbished Xi Systems Expand ISRG's Presence from Hospitals to ASCs?

  • Intuitive Surgical's Market Strategy: Intuitive Surgical is leveraging refurbished da Vinci Xi systems to penetrate cost-sensitive markets and ambulatory surgery centers, enhancing its market access without compromising the pricing of its flagship da Vinci 5 systems.

  • Robotics Adoption by Zimmer Biomet: Zimmer Biomet is focusing on its ROSA robotics strategy to boost growth, reporting significant adoption in knee implants and anticipating enhancements to deepen market penetration.

  • Stereotaxis' GenesisX Platform: Stereotaxis is advancing its GenesisX robotic surgery platform, which has received CE Mark approval in Europe and is set for U.S. launch in 2026, aiming to lower barriers to adoption in robotic electrophysiology procedures.

  • Stock Performance and Future Outlook: Intuitive Surgical's stock has outperformed the industry, with a projected earnings increase for 2025, while the AI sector is expected to see a new wave of growth, presenting investment opportunities in emerging companies.

[object Object]
Preview
9.0
11-14NASDAQ.COM
STXS Obtains FDA Approval for GenesisX to Expand Surgical Robotics

  • FDA Clearance for GenesisX: Stereotaxis (STXS) received FDA 510(k) clearance for its GenesisX robotic system, aimed at enhancing accessibility in endovascular surgical robotics by eliminating infrastructure barriers.

  • Market Impact and Growth Potential: The approval is expected to boost STXS's commercial growth, allowing for broader hospital adoption and increased recurring revenue from disposables, with a market cap of $259.6 million.

  • Design and Installation Advantages: GenesisX features a compact design that integrates magnetic shielding, enabling installation in existing cath labs without modifications, thus reducing costs and complexity.

  • Market Strategy and Future Outlook: Stereotaxis is launching GenesisX in a phased approach while offering flexible financing options to encourage adoption, positioning itself for significant growth in the expanding surgical robotics market projected to reach $23.13 billion by 2030.

[object Object]
Preview
6.0
11-13Benzinga
Roth Capital Affirms Buy Rating for Stereotaxis, Keeps $4 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Stereotaxis Inc (STXS) stock price today?

The current price of STXS is 2.43 USD — it has increased 4.29 % in the last trading day.

arrow icon

What is Stereotaxis Inc (STXS)'s business?

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.

arrow icon

What is the price predicton of STXS Stock?

Wall Street analysts forecast STXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STXS is 4.33 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Stereotaxis Inc (STXS)'s revenue for the last quarter?

Stereotaxis Inc revenue for the last quarter amounts to 7.46M USD, decreased -18.83 % YoY.

arrow icon

What is Stereotaxis Inc (STXS)'s earnings per share (EPS) for the last quarter?

Stereotaxis Inc. EPS for the last quarter amounts to -0.07 USD, decreased -12.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Stereotaxis Inc (STXS)'s fundamentals?

The market is revising Downward the revenue expectations for Stereotaxis, Inc. (STXS) for FY2025, with the revenue forecasts being adjusted by -4.97% over the past three months. During the same period, the stock price has changed by -16.21%.
arrow icon

How many employees does Stereotaxis Inc (STXS). have?

Stereotaxis Inc (STXS) has 139 emplpoyees as of December 05 2025.

arrow icon

What is Stereotaxis Inc (STXS) market cap?

Today STXS has the market capitalization of 228.18M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free